A phase III randomised clinical trial of perioperative therapy (neoadjuvant chemotherapy versus chemoradiotherapy) in locally advanced gallbladder cancers (POLCAGB): study protocol

Reena Engineer, Shraddha Patkar, Shirley Christabel Lewis, Ashutosh Das Sharma, Nitin Shetty, Vikas Ostwal, Anant Ramaswamy, Supriya Chopra, Archi Agrawal, Prachi Patil, Shaesta Mehta, Mahesh Goel, Reena Engineer, Shraddha Patkar, Shirley Christabel Lewis, Ashutosh Das Sharma, Nitin Shetty, Vikas Ostwal, Anant Ramaswamy, Supriya Chopra, Archi Agrawal, Prachi Patil, Shaesta Mehta, Mahesh Goel

Abstract

Introduction: Neoadjuvant chemotherapy (NACT) is considered the current standard for locally advanced gallbladder cancer (GBC). There is no consensus on the optimal neoadjuvant approach. A pilot study from our institution has shown improved overall survival (OS) and progression-free survival (PFS) with neoadjuvant chemoradiation (NACRT). The present randomised phase III trial is designed to compare NACRT with NACT alone and will test the superiority of chemoradiation in terms of tumour downstaging and improvement in OS.

Methods and analysis: Patients with biopsy-proven locally advanced GBC (T3-4) with predefined clinical-radiological features will be randomised to the gemcitabine-based chemotherapy-alone arm or the chemoradiation arm. Patients with resectable disease or with distant metastases will be excluded. The primary end point of the study is to compare OS between the two arms. The secondary end point was to compare PFS, R0 resection rates, acute and late toxicity, postoperative complications and quality of life between the two study arms. The trial is designed to detect an improvement in median OS by 5.5 months in the study arm (11 months in the control group, HR of 0.7) with 80.0% power at a 0.05 significance level. The resultant sample size to achieve this aim is 314 (157 in each arm) over a duration of 5 years with a 10% attrition rate.

Ethics and dissemination: The institutional ethics committee has approved this trial and will be routinely monitoring the trial at frequent intervals. The results of the study will be disseminated via peer-reviewed scientific journals, conference presentations and submission to regulatory authorities.

Registration: The trial is registered with Clinical Trials Registry India (CTRI/2016/08/007199) and ClinicalTrials.gov (NCT02867865). This trial aims to assess the superiority of NACRT over NACT in locally advanced GBCs in terms of improvement in OS. The results of this study will define the optimal neoadjuvant approach in locally advanced GBC.

Trial registration number: NCT02867865; Pre-results.

Keywords: clinical trials; gastrointestinal tumours; radiation oncology.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. de Groen PC, Gores GJ, LaRusso NF, et al. . Biliary tract cancers. N Engl J Med 1999;341:1368–78. 10.1056/NEJM199910283411807
    1. Misra S, Chaturvedi A, Misra NC, et al. . Carcinoma of the gallbladder. Lancet Oncol 2003;4:167–76. 10.1016/S1470-2045(03)01021-0
    1. Jin LX, Pitt SC, Hall BL, et al. . Aggressive surgical management of gallbladder cancer: at what cost? Surgery 2013;154:266–73. 10.1016/j.surg.2013.04.022
    1. Dixon E, Vollmer CM, Sahajpal A, et al. . An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a North American Center. Ann Surg 2005;241:385 10.1097/01.sla.0000154118.07704.ef
    1. Nishio H, Ebata T, Yokoyama Y, et al. . Gallbladder cancer involving the extrahepatic bile duct is worthy of resection. Ann Surg 2011;253:953–60. 10.1097/SLA.0b013e318216f5f3
    1. D’Hondt M, Lapointe R, Benamira Z, et al. . Carcinoma of the gallbladder: patterns of presentation, prognostic factors and survival rate. An 11-year single centre experience. Eur J Surg Oncol 2013;39:548–53. 10.1016/j.ejso.2013.02.010
    1. Sasaki R, Takahashi M, Funato O, et al. . Hepatopancreatoduodenectomy with wide lymph node dissection for locally advanced carcinoma of the gallbladder--long-term results. Hepatogastroenterology 2002;49:912–5.
    1. Araida T, Yoshikawa T, Azuma T, et al. . Indications for pancreatoduodenectomy in patients undergoing lymphadenectomy for advanced gallbladder carcinoma. J Hepatobiliary Pancreat Surg 2004;11:45–9. 10.1007/s00534-003-0867-2
    1. Birnbaum DJ, Viganò L, Ferrero A, et al. . Locally advanced gallbladder cancer: which patients benefit from resection? Eur J Surg Oncol 2014;40:1008–15. 10.1016/j.ejso.2013.10.014
    1. Valle J, Wasan H, Palmer DH, et al. . Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273–81. 10.1056/NEJMoa0908721
    1. Chaudhari VA, Ostwal V, Patkar S, et al. . Outcome of neoadjuvant chemotherapy in "locally advanced/borderline resectable" gallbladder cancer: the need to define indications. HPB 2018;20:841–7. 10.1016/j.hpb.2018.03.008
    1. de Aretxabala X, Losada H, Mora J, et al. . Neoadjuvant chemoradiotherapy in gallbladder cancer. Rev Med Chil 2004;132:51–7.
    1. Morganti AG, Trodella L, Valentini V, et al. . Combined modality treatment in unresectable extrahepatic biliary carcinoma. Int J Radiat Oncol Biol Phys 2000;46:913–9. 10.1016/S0360-3016(99)00487-3
    1. Engineer R, Wadasadawala T, Mehta S, et al. . Chemoradiation for unresectable gall bladder cancer: time to review historic nihilism? J Gastrointest Cancer 2011;42:222–7. 10.1007/s12029-010-9179-3
    1. Engineer R, Sastri S, George GJ. Retrospective Study on the Dosimetric and Clinical Evaluation of Duodenal Toxicity in Those Who Underwent Radiation Therapy for Cancers of the Upper Gastrointestinal Tract and Gynecological Cancers Who Received Extended Field Radiotherapy. Int J Radiat Oncol Biol Phys 2017;99:E147 10.1016/j.ijrobp.2017.06.952
    1. Engineer R, Goel M, Chopra S, et al. . Neoadjuvant chemoradiation followed by surgery for locally advanced gallbladder cancers: a new paradigm. Ann Surg Oncol 2016;23:3009–15. 10.1245/s10434-016-5197-0
    1. Grégoire V, Mackie TR. State of the art on dose prescription, reporting and recording in Intensity-Modulated Radiation Therapy (ICRU report No. 83). Cancer/Radiothérapie 2011;15:555–9. 10.1016/j.canrad.2011.04.003
    1. Eisenhauer EA, Therasse P, Bogaerts J, et al. . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47. 10.1016/j.ejca.2008.10.026
    1. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205 10.1097/

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren